Novartis Ag

Novartis Vaccines & Diagnostics, Gmbh

Tinya Abrams

Paul Andrew Barsanti

Thomas Huber

David Duhl

Steven Bruce Cohen

Paul A Renhowe

Annette Olga Walter

Kathy Miller

Kathrin Ulrike Tissot-Daguette

Siew Ho Schleyer

Catrin Finner

Weibo Wang

Savithri Ramurthy

Sharadha Subramanian

Ryan N Constantine

Kris Mendenhall

Nathan Brammeier

Megan C Phillips

Hong Yang

Mark Knapp

Sabina Pecchi

Kenneth Walter Bair

Eric J Martin

Rama Jain

Liana Marie Lagniton

Elisa Jazan

Elizabeth J Mieuli

Kelly Wayman

Anu Sharma

Rustum Boyce

Kay Huh

Vincent P Le

Christie P Fanton

Jean-Michel Rene Rondeau

Bernhard Hubert Geierstanger

Weijia Ou

William Mallet

Matthew John Meyer

Larry Alexander Gaither

Dylan L Daniel

Jason Damiano

Clemens Dürr

Michel Faure

Katherine Rendahl

Yia Xia

Daniel Menezes

Yi Xia

Rustum S Boyce

Cheng Hu

Wooseok Han

Yue Pan

Yu Ding

Liana Marie Lagnition

Xia Yia

Clemens DÜRR

The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

CKIT antibody drug conjugates

The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.

Pharmaceutical combination comprising LSZ102 and ribociclib

The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.

Pharmaceutical combination comprising LSZ102 and alpelisib

This application discloses anti-P-cadherin antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments. The invention also relates to methods of treating cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.

Antibody drug conjugates

cKIT antibody drug conjugates

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: 

Substituted imidazole derivates

The invention provides novel compounds having a substituted imidazole ring, and methods of using such compounds for the treatment of certain disorders such as hematological cancers and solid tumors. The compounds of the invention are tri-substituted imidazole derivatives that inhibit KSP. These compounds are also useful for the treatment of drug resistant tumors, such as solid tumors that express elevated levels of P-glycoprotein.

Kinesin inhibitors as cancer therapeutics

The present invention provides triazole compounds of Formula I: 

Triazole compounds as KSP inhibitors

Substituted imidazole derivatives

The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses of the compounds. The compounds of the invention have the following general formula: 

Substituted imidazole compounds as KSP inhibitors

Growing community of inventors

Richmond, CA, United States of America

Tinya Abrams